Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.45 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | CDC25C | P30307 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401288 | 0.93 | CDC25A (0.43) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL3813513 | 0.91 | CDC25A (0.45) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL2401633 | 0.88 | CDC25A (0.46) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL2401313 | 0.79 | — | — | |
| SCHEMBL2400262 | 0.79 | CDK4 (0.47) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL2399165 | 0.78 | ALDH1A1 (0.34) | MEN1BLMKMT2ATDP1 | |
| SCHEMBL2399950 | 0.78 | CDC25A (0.38) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL2404200 | 0.77 | SETD7 (0.34) | MEN1KMT2ATDP1 | |
| SCHEMBL2400499 | 0.76 | CDK4 (0.42) | CDK4KMT5AMEN1THRBCCND1 | |
| SCHEMBL2398593 | 0.76 | CDK4 (0.34) | CDK4KMT5AMEN1THRBCCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | claimed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | claimed |
| US-8017637-B2 | Inhibitors of cdc phosphatases | IPSEN PHARMA S.A.S. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | CDC25C, CDC25A, CDC25B | CDK4 72/4885KMT5A 1673/4885MEN1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.